Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts

NCT03886649 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03886649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03886649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1
Overall status
Terminated
Start date
November 4, 2019
Completion date
March 8, 2022
Enrollment
7 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma